Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 29, Issue 23, 2011, Pages 3173-3178

  Kantarjian, Hagop ^a   O'Brien, Susan ^a   Jabbour, Elias ^a   Shan, Jenny ^a   Ravandi, Farhad ^a   Kadia, Tapan ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Borthakur, Gautam ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DEATH; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERCEPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051821734     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4169     Document Type: Article

References (19)

1. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003
2. Kantarjian H, Talpaz M, O'Brien S, et al: Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 108:1835-1840, 2006
3. Cortes J, Silver R, Kantarjian H: Chronic myeloid leukemia, in Hong W, Bast R, Hait W, et al (eds): Cancer Medicine (ed 8). Shelton, CT, People's Medical Publishing House, 2010, pp 1582-1590
4. Kantarjian H, O'Brien S, Cortes J, et al: Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97:1033-1041, 2003
5. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423-1432, 2003
6. Hughes T, Hochhaus A, Branford S, et al: Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon Versus STI571 (IRIS). Blood 116:3758-3765, 2010
7. Druker B, Guilhot F, O'Brien S, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006
8. Kantarjian H, Giles F, Wunderle L, et al: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354: 2542-2551, 2006
9. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly amn107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110:3540-3546, 2007
10. Hochhaus A, Kantarjian H, Baccarani M, et al: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007
11. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270, 2010
12. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259, 2010
13. O'Brien SG, Guilhot F, Goodman JM, et al: International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood 112:76, 2008 (abstr 186)
14. Kantarjian H, O'Brien S, Shan J, et al: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia. Cancer 112:837-845, 2008
15. Quintas-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321, 2009
16. Cortes J, Jones D, O'Brien S, et al: Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 28:392-397, 2010
17. Cortes J, Jones D, O'Brien S, et al: Results of dasatinib therapy in patients with early chronicphase chronic myeloid leukemia. J Clin Oncol 28:398-404, 2010
18. de Lavallade H, Apperley J, Khorashad J, et al: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention to treat analysis. J Clin Oncol 26:3358-3363, 2008
19. Garg RJ, Kantarjian H, O'Brien S, et al: The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: Long-term follow-up. Blood 114:4361-4368, 2009